Abstract

Background: Forty-four strains isolated from a cohort of cutaneous leishmaniasis (CL) patients who did or did not respond to one course of treatment with meglumine antimoniate were investigated to explore genetic polymorphisms in parasite kinetoplast DNA minicircles. Leishmania (Viannia) braziliensis strains isolated from responder (R) and non-responder (NR) patients who acquired infection in Rio de Janeiro or in other Brazilian states were studied using low-stringency single-specific primer polymerase chain reaction (LSSP-PCR) to identify genetic polymorphisms. Results: Polymorphisms were observed in parasites recovered from patient lesions. No association was found between a specific genotype and R or NR patients. Phenetic analysis grouped the genotypes into three main clusters, with similarity indices varying from 0.72 to 1.00. Although no specific genotype association was detected, at least one group of L. (V.) braziliensis genotypes that circulates in Rio de Janeiro was discriminated in clusters I and III, showing phenotypes of good and poor responses to treatment, respectively. Cluster I comprised parasite profiles recovered from R patients from Rio de Janeiro and in cluster III, NR samples were prevalent. Cluster II comprised 24 isolates, with 21 from Rio de Janeiro and three from other states, equally distributed between R and NR patients. Additionally, we found that parasites sharing all common genetic characteristics acted differently in response to treatment. Conclusions: These results are of clinical-epidemiological importance since they demonstrate that populations of L. (V.) braziliensis that exhibit high levels of genetic similarity also display different phenotypes associated with meglumine antimoniate responses in cutaneous leishmaniasis patients.

Highlights

  • Leishmaniases are a group of zoonotic or anthroponotic diseases caused by different species of the genus Leishmania

  • Montenegro skin test (MST) values were statistically higher in the R group (p = 0.048), and the NR group was more reactive to IIF as compared with the R group (p = 0.001)

  • Pentavalent antimonials have been used to treat all clinical forms of leishmaniasis for the previous 70 years

Read more

Summary

Introduction

Leishmaniases are a group of zoonotic or anthroponotic diseases caused by different species of the genus Leishmania. TL presents as two distinct clinical forms: cutaneous and mucosal, depending on the species of parasite involved in the infection and the immune response of the host. Cutaneous leishmaniasis (CL) comprises clinical manifestations occurring exclusively on the skin [2]. In Brazil, the Ministry of Health [2] recommends 10 to 20 mg Sb5+/kg/day for 20 consecutive days, not exceeding 1215 mg Sb5+ per day. The efficacy of this regimen in regions where Leishmania (Viannia) braziliensis infections predominate varies between 51.1% and 90%. Antimony resistance is not a national public health concern, and from 50 to 100% of re-treated patients have a favorable outcome [2]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call